Literature DB >> 7564499

CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications.

P C de Bruin1, H J Gruss, P van der Valk, R Willemze, C J Meijer.   

Abstract

CD30 expression is found on Hodgkin and Reed-Sternberg cells, anaplastic large cell lymphoma cells and on activated B or T lymphocytes. Recently CD30 was shown to be a transmembrane receptor that is significantly homologous to the tumor necrosis factor receptor (TNFR) family. Ligands for most members of this family, including CD30, have now been identified. This review summarizes the role of the different TNFR family members in lymphocyte proliferation and differentiation in an attempt to understand more clearly the role of CD30 expression in the pathogenesis and clinical behavior of non-Hodgkin's lymphomas. We state that CD30 expression is of prognostic relevance in primary cutaneous and nodal T cell lymphomas in contrast to the absence of clinical relevance of CD30 expression in B cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7564499

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  10 in total

1.  Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene.

Authors:  E J Croager; A M Gout; L J Abraham
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  Cutaneous T-cell lymphoma with adrenal insufficiency.

Authors:  J F Blaikley; P Atkinson; M K Almond
Journal:  J R Soc Med       Date:  2003-10       Impact factor: 5.344

3.  Polyclonal proliferation of plasma cells associated with marked hypergammaglobulinemia in an elderly patient.

Authors:  Hitoshi Ohno; Hideaki Tanaka; Hisashi Sakai; Tatsuya Katsurada; Yataro Yoshida
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

4.  Plasma-soluble CD30 in childhood tuberculosis: effects of disease severity, nutritional status, and vitamin A therapy.

Authors:  W A Hanekom; G D Hussey; E J Hughes; S Potgieter; R Yogev; I J Check
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

5.  Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1.

Authors:  Meili Zhang; Zhengsheng Yao; Hiral Patel; Kayhan Garmestani; Zhuo Zhang; Vladimir S Talanov; Paul S Plascjak; Carolyn K Goldman; John E Janik; Martin W Brechbiel; Thomas A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-08       Impact factor: 11.205

6.  Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors.

Authors:  Meili Zhang; Zhengsheng Yao; Zhuo Zhang; Kayhan Garmestani; Carolyn K Goldman; Jeffrey V Ravetch; John Janik; Martin W Brechbiel; Thomas A Waldmann
Journal:  Blood       Date:  2006-03-21       Impact factor: 22.113

7.  Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack.

Authors:  Andreas A Hombach; André Görgens; Markus Chmielewski; Florian Murke; Janine Kimpel; Bernd Giebel; Hinrich Abken
Journal:  Mol Ther       Date:  2016-04-26       Impact factor: 11.454

8.  Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility.

Authors:  Bin Li; Steven A Eschrich; Anders Berglund; Melissa Mitchell; David Fenstermacher; Hadi Danaee; Hongyue Dai; Daniel Sullivan; William L Trepicchio; William S Dalton
Journal:  JMIR Res Protoc       Date:  2017-03-20

9.  CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells.

Authors:  Marika Guercio; Domenico Orlando; Stefano Di Cecca; Matilde Sinibaldi; Iolanda Boffa; Simona Caruso; Zeinab Abbaszadeh; Antonio Camera; Biancamaria Cembrola; Katia Bovetti; Simona Manni; Ignazio Caruana; Roselia Ciccone; Francesca Del Bufalo; Pietro Merli; Luciana Vinti; Katia Girardi; Annalisa Ruggeri; Cristiano De Stefanis; Marco Pezzullo; Ezio Giorda; Marco Scarsella; Rita De Vito; Sabina Barresi; Andrea Ciolfi; Marco Tartaglia; Lorenzo Moretta; Franco Locatelli; Concetta Quintarelli; Biagio De Angelis
Journal:  Haematologica       Date:  2021-04-01       Impact factor: 9.941

10.  Study of the expression of CD30 in pterygia compared to healthy conjunctivas.

Authors:  Yonathan Garfias; Víctor Manuel Bautista-De Lucio; Cynthia García; Angel Nava; Leonardo Villalvazo; María Carmen Jiménez-Martínez
Journal:  Mol Vis       Date:  2009-10-17       Impact factor: 2.367

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.